Idiopathic membranous glomerulonephritis

This trial tests whether rituximab, an infusion drug that calms certain immune cells, can help people with idiopathic membranous nephropathy and nephrotic syndrome. Participants receive either rituximab or a placebo, and the study tracks how many achieve a significant reduction i…

This study tests whether the drug zanubrutinib can help people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 178 participants will receive either zanubrutinib or the standard drug tacrolimus. The goal is to see if zanubrutinib reduces pr…

This study tests a drug called obinutuzumab against a standard treatment (tacrolimus) in 142 adults with primary membranous nephropathy, a kidney disease that lets protein leak into urine. The goal is to see if obinutuzumab can bring about complete remission (no protein in urine)…

This was a planned study to compare a newer drug, obinutuzumab, against a standard treatment (steroids plus cyclophosphamide) for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The goal was to see which treatment worked better and had fe…

This study tests a new drug, zuberitamab, in 135 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. Participants receive either zuberitamab (two doses two weeks apart) or the standard drug cyclosporine. The main goal is to see if zuberitam…

This study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…

This observational study compares two common blood tests—creatinine and cystatin C—to see which one better estimates actual kidney function in people with nephrotic syndrome. Researchers will use stored blood samples from 50 participants in three ongoing clinical trials. The goal…